- Home
- OMER vs VLGEA Comparison
OMER vs VLGEA Comparison
Compare OMER & VLGEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- VLGEA
- Stock Information
- Founded
- OMER 1994
- VLGEA 1937
- Country
- OMER United States
- VLGEA United States
- Employees
- OMER N/A
- VLGEA N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- VLGEA Food Chains
- Sector
- OMER Health Care
- VLGEA Consumer Staples
- Exchange
- OMER Nasdaq
- VLGEA Nasdaq
- Market Cap
- OMER 513.8M
- VLGEA 480.8M
- IPO Year
- OMER 2009
- VLGEA N/A
- Fundamental
- Price
- OMER $8.83
- VLGEA $34.35
- Analyst Decision
- OMER Strong Buy
- VLGEA
- Analyst Count
- OMER 5
- VLGEA 0
- Target Price
- OMER $27.50
- VLGEA N/A
- AVG Volume (30 Days)
- OMER 1.7M
- VLGEA 37.1K
- Earning Date
- OMER 11-13-2025
- VLGEA 12-02-2025
- Dividend Yield
- OMER N/A
- VLGEA 2.95%
- EPS Growth
- OMER N/A
- VLGEA 12.16
- EPS
- OMER N/A
- VLGEA 3.81
- Revenue
- OMER N/A
- VLGEA $2,320,690,000.00
- Revenue This Year
- OMER N/A
- VLGEA N/A
- Revenue Next Year
- OMER N/A
- VLGEA N/A
- P/E Ratio
- OMER N/A
- VLGEA $8.98
- Revenue Growth
- OMER N/A
- VLGEA 3.76
- 52 Week Low
- OMER $2.95
- VLGEA $29.64
- 52 Week High
- OMER $13.60
- VLGEA $40.15
- Technical
- Relative Strength Index (RSI)
- OMER 67.40
- VLGEA 55.04
- Support Level
- OMER $6.24
- VLGEA $33.54
- Resistance Level
- OMER $7.06
- VLGEA $34.48
- Average True Range (ATR)
- OMER 0.54
- VLGEA 0.87
- MACD
- OMER 0.02
- VLGEA 0.35
- Stochastic Oscillator
- OMER 99.65
- VLGEA 81.17
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.